Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic medication. It is traditionally used against worms, but more recently found to be effective against mites and some lice too. Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas and stop transmission of lymphatic filariasis around the world.
A team of researchers at the Genomics Research Center, Academia Sinica, in Taiwan, evaluated the efficacy of 2,855 agents against SARS-CoV-2.
A small pilot study suggests that early administration of ivermectin can reduce viral loads and symptom duration in patients with mild COVID-19, which in turn could help reduce viral transmission.
A double-blind, randomized, placebo-controlled clinical trial has recently demonstrated that Ivermectin, an anti-parasitic drug, can reduce in-hospital mortality rate of COVID-19 patients.
Healthcare workers in tropical and sub-tropical settings where strongyloidiasis is prevalent or caring for patients who have travelled to such areas, need to maintain a high level of awareness about the use of corticosteroids, including when this class of anti-inflammatories is given to patients suspected of infection with SARS-CoV-2.
A team of researchers at the Institut Pasteur in France has found that ivermectin prevented clinical deterioration in infected animals. The drug also reduced the inflammatory cytokines, interleukin-6 and 10 (IL-6 and IL-10) in lung tissue, which leads to more favorable clinical outcomes in treated animals.
In 2019, 538.1 million people were treated for lymphatic filariasis (LF) in 38 countries that implemented mass drug administration (MDA) of populations at risk of the disease, as recommended by the World Health Organization (WHO).
Today, the U.S. Food and Drug Administration approved a lotion to treat head lice for nonprescription, or over-the-counter (OTC), use through a process called a prescription (Rx)-to-OTC switch.
Researchers in Argentina have conducted a pre-clinical study demonstrating the safety and pharmacokinetic performance of a new nasal spray formulation designed to suppress the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).
As the search for effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibitors continues, a recent study by Yale University School of Medicine researchers published on the preprint server bioRxiv in October 2020 reports the inhibitory effect of the drug merofloxacin on frameshifting during SARS-CoV-2 replication.
COVID-19 continues to wreak havoc globally, with over one million deaths to date. Yet what if an existing vaccine could make COVID-19 less deadly? A study just published put the theory to test, with promising results.
Researchers have developed a method to spur the production of new antibiotic or antiparasitic compounds hiding in the genomes of actinobacteria, which are the source of drugs such as actinomycin and streptomycin and are known to harbor other untapped chemical riches.
A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.
It might seem paradoxical to suggest immunosuppression could play a role in managing COVID-19. The seemingly logical therapeutic option for this disease would be an antiviral.
Researchers at Washington University School of Medicine in St. Louis have received two grants from the National Institutes of Health totaling more than $5 million to study two types of parasitic worm infection that cause devastating illness in millions of people worldwide.
Clínica Universidad de Navarra and the Barcelona Institute for Global Health (ISGlobal), a centre supported by the "la Caixa" Foundation, have launched a clinical trial to investigate the efficacy of ivermectin against COVID-19.
Clinical leaders from the University of Kentucky's Markey Cancer Center, College of Medicine and College of Pharmacy have launched a clinical trial for experimental therapies to treat patients infected with COVID-19.
Contrary to the warnings issued by health agencies worldwide against cigarette smoking amid the coronavirus disease (COVID-19), a new paper suggests the possibility that nicotine, a component of tobacco, could prevent coronavirus infection.
A new paper published on the preprint server medRxiv in April 2020 shows that the use of the already approved drug ivermectin in clinical trials to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)s not feasible. This contradicts earlier reports of its ability to suppress the virus in vitro.
Around the world, scientists race to develop a vaccine or treatment against the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, a team of researchers has found that a drug already available around the world can kill the coronavirus in a lab setting in just 48 hours.
A collaborative study led by Monash University's Biomedicine Discovery Institute in Melbourne, Australia, with the Peter Doherty Institute of Infection and Immunity, has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.